Alamar Biosciences filings document its transition to a Nasdaq-listed public company, its proteomics business, and its formal reporting of operating results, capital structure, and governance. Registration materials describe the company’s NULISA-based Precision Proteomics platform, product categories, single-segment structure, and common stock offering.
The company’s 8-K filings cover public-company events including quarterly financial results, completion of its initial public offering, amended and restated certificate of incorporation, amended and restated bylaws, and related exhibits. Its S-1/A registration statement documents IPO-related disclosures, risk factors, business description, securities registration, and governance information.
Alamar Biosciences, Inc. (ALMR) reports sales of 280,458 common shares by Qiming-affiliated entities on October 23 and October 26, 2026. The shares were held of record by Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming Venture Partners VIII Investments, LLC, and Qiming Venture Partners VIII-HC, L.P. Reported weighted-average prices were $29.35, $30.23, and $30.85 per share on October 23, and $30.52 and $31.07 per share on October 26. No Rule 10b5-1 plan is reported.
Alamar Biosciences, Inc. (ALMR) reported sales of 342,626 common shares by four Qiming-affiliated record holders—Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming Venture Partners VIII Investments, LLC and Qiming Venture Partners VIII-HC, L.P.—on October 21 and October 22, 2026. Weighted-average prices were $29.01, $29.75 and $30.79 per share on October 21 and $29.00, $29.59 and $30.81 per share on October 22. No Rule 10b5-1 plan is reported.
Alamar Biosciences, Inc. reported that four Qiming entities indirectly sold 217,512 shares of common stock on October 19 and 20, 2026. The shares were held of record by Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming Venture Partners VIII Investments, LLC, and Qiming Venture Partners VIII-HC, L.P. Reported weighted-average prices were $26.34 per share on October 19 and $26.63, $27.93 and $28.44 per share on October 20. No Rule 10b5-1 plan is reported.
Alamar Biosciences, Inc. (ALMR) common shares were sold indirectly by four Qiming holder entities: Qiming Managing Directors Fund VI, L.P., Qiming Venture Partners VI, L.P., Qiming Venture Partners VIII Investments, LLC, and Qiming Venture Partners VIII-HC, L.P. Sales totaled 173,673 shares on October 15 and 16, 2026. Prices included $27.02 and $28.26 per share, plus a $27.73 weighted-average price for multiple transactions at prices from $27.26 to $28.23. No Rule 10b5-1 plan is reported.
Alamar Biosciences, Inc. (ALMR) is named in a Rule 144 notice by affiliate Qiming Venture Partners VIII-HC, L.P., which reports a proposed sale of 435,468 common shares with an aggregate market value of $10,242,000. J.P. Morgan Securities LLC is listed as broker, and October 14, 2026 is the approximate sale date.
Alamar Biosciences, Inc. (ALMR) reported a proposed sale by affiliate Qiming Venture Partners VIII Investments, LLC of 363,729 common shares, with an aggregate market value of $8,555,000 and an approximate sale date of October 14, 2026. J.P. Morgan Securities LLC is listed as broker for the proposed transaction.
Alamar Biosciences, Inc. (ALMR) is the issuer in a notice that Qiming Venture Partners VI, L.P., identified as an affiliate, proposes to sell 1,558,858 common shares. The notice lists an aggregate market value of $36,664,000.00, J.P. Morgan Securities LLC as broker, and Nasdaq Stock Market as the exchange. The approximate sale date is October 14, 2026; the notice lists 69,392,766 shares outstanding.
Alamar Biosciences, Inc. (ALMR) is the issuer whose affiliate, Qiming Managing Directors Fund VI, L.P., reported a proposed sale of 41,945 common shares through J.P. Morgan Securities LLC. The notice lists an aggregate market value of $987,000 and an approximate sale date of October 14, 2026. It lists 69,392,766 common shares outstanding. The listed acquisition records cite private investments in Series A-3, Series A-4 and Series B preferred shares, automatically converted into common stock upon IPO.
Alamar Biosciences, Inc. (ALMR) reported that General Counsel John L. Brottem received equity awards on September 14, 2026. He was granted 29,000 shares of common stock in the form of restricted stock units and 85,000 stock options with an exercise price of $27.99 per share, all held directly.
The restricted stock units vest over roughly six years, with one-quarter vesting on November 21, 2027 and the remainder vesting in twelve equal quarterly installments thereafter, subject to his continuous service. The options expire on September 13, 2036 and vest one-quarter on September 14, 2027, with the balance vesting in 36 equal monthly installments, also contingent on continuous service. No Rule 10b5-1 trading plan is reported for these awards.
Alamar Biosciences, Inc. (ALMR) had its General Counsel, John L. Brottem, file an initial statement of beneficial ownership on Form 3. The filing reports no equity transactions and no reportable holdings of Alamar Biosciences securities by Brottem at the time of filing.